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Abstract
This guidance document is intended to assist the applicant in the preparation and the presentation
of an application, as foreseen in Article 7.6 of Regulation (EC) No 1831/2003, for the authorisation of
additives for use in animal nutrition. It speciﬁcally covers the assessment of the safety for the
consumer.
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Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. Moreover, Regulation (EC) No 429/20082 provides detailed rules
for the implementation of Regulation (EC) No 1831/2003 as regards the preparation and the
presentation of applications and the assessment and the authorisation of feed additives.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) has
adopted a series of guidance documents which aim at complementing Regulation (EC) No 429/2008 to
support applicants in the preparation and submission of technical dossiers for the authorisation of
additives for use in animal nutrition according to Regulation (EC) No 1831/2003.
The European Food Safety Authority (EFSA) asked its FEEDAP Panel to:
1) identify from the current guidance documents, those that need to be updated, taking into
consideration the most recent scientiﬁc developments and the experience gained in the
assessment of feed additives;
2) update the guidance documents in need of revision accordingly; this activity can be
conducted in different rounds of activities on the basis of the priorities identiﬁed and on the
feasibility of the revision according the resources available;
3) taking into account the sensitivity and the relevance of some of the guidance documents
under revision and the entity of the revision itself (e.g. substantial or not), consider
initiatives like preparatory info-sessions or public consultations of the draft guidance
documents. The relevant comments received in either step will have to be considered and
addressed if appropriate in the ﬁnal version of the guidance documents.
The ﬁrst of the terms of reference was addressed by a statement of the EFSA FEEDAP
Panel (2016), in which it was identiﬁed the need to update most of the guidance documents that it
produced and set priorities for this update.
This output addresses the second and third terms of reference with regard to the update of the
guidance documents dealing with the assessment of the safety of feed additives for the consumer. This
guidance document underwent a public consultation (EFSA, 2017).
Scope of the guidance
This guidance document is intended to assist the applicant in the preparation and the presentation
of its application for authorisation of a feed additive, as foreseen in Article 7.6 of Regulation (EC)
No 1831/2003. This document does not substitute for the obligation of an applicant to comply with the
requirements of Regulation (EC) No 1831/2003 and its implementing rules.
This document provides guidance on how to assess the safety for the consumer. This guidance is
divided into ﬁve sections. The introduction provides the principles of the assessment of consumer
safety. A catalogue of studies that may be needed is provided in Section 2 while the requirements for
the different additives are listed in Section 3. Section 4 describes how to derive a highest safe intake
for the consumer based on the outcome of the above studies. The safety for the consumer is assessed
by comparing the exposure of the consumer to residues in food products to this safe intake. Finally,
Section 5 describes how to calculate maximum residue levels (MRLs), when needed.
1. Introduction
The studies described in this guidance should be based on the additive for which authorisation is
sought. As a principle, studies necessary to assess consumer safety should be carried out with the
active substance. However, when the active substance is present in a fermentation product, the
fermentation product should be tested. The fermentation product tested must be identical to that to
be used in the commercial product. Where an additive has a number of active components, ideally
each should be separately assessed and then consideration given to potential interactions. For complex
mixtures, especially when the components cannot be fully identiﬁed/separated, the whole mixture
should be assessed.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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When data are provided in publications, evidence must be provided that the additive used in these
studies is identical to that under application or, if not, would still allow conclusions on the additive
under application to be made. For additives produced by fermentation, this includes the production
strain.
Applicants should justify the omission from the dossier of any data or any deviations from the
requirements detailed in this guidance.
Data submitted should allow an assessment of the safety for consumers exposed to food derived
from animals given feed or water containing the additive. This should consider:
i) the metabolic fate and residues of the additive in the target species and laboratory animals,
ii) the potential toxicity of the additive,
iii) consumer exposure resulting from the consumption of food derived from animals exposed to
the highest proposed use level of the additive.
2. Studies for the assessment of consumer safety
2.1. Absorption, distribution, metabolism and excretion (ADME) and
residue studies
The aim of these studies is:
i) to establish the metabolic fate of the active substance(s) in laboratory animals and the target
species as a basis for its toxicological evaluation,
ii) to identify and quantify residues (parent compound and metabolites) of toxicological relevance
in edible tissues and products and select the marker residue when required,
iii) to establish the kinetics of total residues and the marker residue in tissues/products.
2.1.1. ADME studies
The studies should follow the principles described in the Organisation for Economic Co-operation
and Development (OECD) guideline 417 for the testing of chemicals as follows: ‘Studies examining the
toxicokinetics [. . .] of a chemical substance are conducted to obtain adequate information on its
absorption, distribution, biotransformation (i.e. metabolism) and excretion [. . .]. Basic [ADME]
parameters determined from these studies will also provide information on the potential for
accumulation of the test substance in tissues and/or products and the potential for induction/inhibition
of biotransformation as a result of exposure to the test substance [. . .] Adequate toxicokinetic data will
be helpful to support the further acceptability and applicability of quantitative structure-activity
relationships, read-across or grouping approaches in the safety evaluation of substances. [. . .]
A radiolabelled test substance using 14C should be used for all mass balance and metabolite
identiﬁcation aspects of the study; however, if it can be demonstrated that [. . .] mass balance and
metabolite identiﬁcation can be adequately evaluated using the unlabelled test substance, [and] the
analytical speciﬁcity and sensitivity of the method used with non-radioactive test substance is equal to
or greater than that which could be obtained with the radiolabelled test substance,3 then, radiolabelled
compound does not need to be used. Furthermore, other radioactive and stable isotopes may be used,
particularly if the element is responsible for or is a part of the toxic portion of the compound. If
possible, the radiolabel should be located in a core portion of the molecule which is metabolically
stable (it is not exchangeable, is not removed metabolically as CO2, and does not become part of the
one-carbon pool of the organism). Labelling of multiple sites or speciﬁc regions of the molecule may
be necessary to follow the metabolic fate of the compound’.
A justiﬁcation of the choice and the molecular position of the label should be given, its speciﬁc
(radio)activity, (radio)chemical purity and stability described.
2.1.1.1. ADME study in target animals
A study should be performed on a limited number of animals (e.g. at least three per sex for
chickens for fattening, three for dairy cows) administered orally a single dose of the active substance.
The dose should correspond to the highest proposed use level in feed. Mass balance, absorption,
distribution (plasma/blood, tissues), excretion (urine, bile, faeces, milk or eggs, expired air (i.e. 14CO2),
excretion via gills, where appropriate) and bioavailability if appropriate, should be measured.
3 Chromatographic techniques couple to high-resolution mass spectrometric methods.
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Excreta (and plasma, if appropriate) should be collected for identiﬁcation and quantiﬁcation of
unchanged test substance and metabolites. Efforts should be made to identify all metabolites present
at 5% or greater of the administered dose or 10% of total radioactivity in the animal (whichever
allows the greatest number of metabolites to be detected) and to provide a metabolic scheme for the
test substance. Identiﬁcation refers to the exact structural determination of components.
Metabolic pathways are assumed to be similar within a species. Therefore, not each category within
a species needs to be examined. For example:
• if data for chickens for fattening are provided, no data are necessary for chickens reared for
laying, and in case of laying hens, only additional data for egg are required.
• if data for calves for rearing are provided, no additional data for cattle for fattening is required
(and vice versa), and in case of dairy cows, only additional data for milk are required.
• if data for pigs for fattening are provided, no studies for piglets or sows are required (and vice
versa).
Metabolic pathways are also assumed to be similar within physiologically similar species (Table 1).
If metabolism data are available for the species/categories of column 1 in Table 1, then no speciﬁc
studies need to be performed with the physiologically related species indicated in column 2. Otherwise,
an indication of the metabolic pathway in the species under application is required. A comparison of
metabolic proﬁles can be obtained through in vitro or in vivo studies.
2.1.1.2. ADME study in laboratory animals
The purpose of these studies is to determine whether the metabolites to which the consumer will
be exposed by consuming food products from animals fed with the additive are also produced by
metabolism in the laboratory animals used in toxicological testing.
The proximity of metabolism in the target animals and laboratory animals may be demonstrated by
comparison of metabolic proﬁles established by in vitro or in vivo studies.
If proximity cannot be established in vitro, then a metabolism study made with the laboratory
animal is required. The laboratory animal species (and strain) used for the in vitro or in vivo
comparative metabolism studies should be the same as used in toxicological studies to deﬁne the
lowest no observed adverse effect level (NOAEL).
If metabolic proximity is not given, the applicant should address by other means the relevance to
consumer safety of the speciﬁc metabolite(s) produced in the target species. If metabolic studies are
available in humans, these data should be taken into consideration.
2.1.1.3. In vitro studies
Several questions concerning the metabolism of the substance may be addressed in in vitro studies
using appropriate test systems. Fresh liver tissue slices, primary cell cultures from liver cells, freshly
isolated hepatocytes and subcellular fractions (e.g. microsomes and cytosol or S9 fraction) from liver
may be used to study possible metabolites.
2.1.2. Residue studies
The aim of residue studies is: (i) to determine total residues and (ii) to measure the marker residue
of the active substance, in edible tissues and products at metabolic equilibrium and during withdrawal
Table 1: Extrapolation of metabolism data from certain species/categories to physiologically related
species
From To physiologically related species
Chickens for fattening Other poultry for fattening (e.g. turkeys, ducks, geese, pheasants, quail,
guinea fowl, ostrich)
Laying hens Other birds kept for egg production (e.g. ducks, geese, pheasants,
quail, ostrich)
Pigs Other Suidae
Calves or cattle Other growing ruminants (e.g. sheep, goat, buffalo) at the
corresponding developmental stage
Dairy cows Other dairy ruminants (e.g. goat, sheep, buffalo)
Salmon or trout Other ﬁsh
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time. The marker residue is the residue selected for assay whose concentration is in a known
relationship to total residues in tissues and products. Edible tissues are muscle/ﬂesh, liver, kidney and
fat (skin plus fat for poultry); products are milk, eggs and honey. The measurement of the active
substance and its major metabolite(s) in excreta (urine, faeces, bile), edible tissues and products
should be performed (see Section 2.1.1.1). Depending on structural alerts or toxicological
considerations, the measurement of minor metabolites in tissues and products could be necessary.
Consideration should also be given to the amount and nature of non-extractable residues in edible
tissues/products (covalently bound residues or incorporation into physiological body constituents such
as fatty acids/lipids, carbohydrates or amino acids/proteins).
The marker residue should be selected and the ratios marker to total residues should be given for
edible tissues and products, if appropriate. Where appropriate, metabolites of toxicological signiﬁcance
should also be measured.
The dose applied should correspond to the highest proposed use level and should preferably be
administered via feed or water for drinking to animals until metabolic equilibrium (by default, until
plasma steady state) is reached.
For those additives in which the consequences of the rate of depletion on residue concentration are
needed (e.g. when MRLs are considered necessary), residues in tissues should be measured at
additional sampling points after withdrawal (preferably three), spaced according to the rate of
depletion from tissues. The same number of animals as listed in Sections 2.1.2.1 and 2.1.2.2 applies
for each time point, respectively.
Two types of studies are in principle required:
2.1.2.1. Total residue study
A study of total residues should be made with the labelled active substance, administered until
metabolic equilibrium in tissues is reached. The minimum number of healthy animals selected for
tissue analysis is three for dairy cows, sows and laying hens, four for cattle, pigs, poultry and related
minor species and rabbits, 10 for salmonids and other aquatic species. Equal sex distribution should be
applied as appropriate. For poultry species, age/body weight of the birds used for this study should
reﬂect approximately the middle of the production period. For residues in products, the following
number of animals should be used: for milk, at least eight cows (24 h pooled milk); for eggs, the
sufﬁcient number of laying hens to collect 10 eggs; for honey, six bee hives. The parent compound
and identiﬁed metabolites (see Section 2.1.1.1) should be determined in edible tissues and products.
The marker residue should be selected from this study, and the ratios marker to total residues should
be established.
2.1.2.2. Marker residue study
The minimum number of healthy animals selected for tissue analysis is four for dairy cows, cattle,
pigs, sows and related minor species and rabbits, six for poultry, and 10 for salmonids and other
aquatic species. Equal sex distribution should be applied as appropriate. For residues in products, the
same number of animals as in Section 2.1.2.1 applies. The minimum administration period of the
additive should be 28 days, for animals for fattening for the 28 days prior to slaughter. The samples
should be collected at the end of the administration period. Measurements of the marker residue
concentration (MRC) should use a validated analytical method with sufﬁcient sensitivity.
2.1.3. Relevance of residues to safety assessment
As a ﬁrst approach, total residues measured in edible tissues and products from target animals
administered the (radio)labelled active substance are considered of toxicological relevance.
In a second step, toxicological relevant residues could be derived from total residues by
discounting, on a quantitative basis:
– the labelled fraction incorporated into physiological endogenous compounds and
– metabolites with evidence of a reduced toxicological relevance with regard to the parent
compound.
Identiﬁcation of toxicologically relevant metabolites can make use of structural alerts.
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2.2. Toxicological studies
The safety of the additive is assessed on the basis of the toxicological studies performed in vitro
and in vivo on laboratory animals.
The basic set of toxicological studies includes studies on:
1) genotoxicity
2) subchronic oral toxicity
This may be augmented as necessary by studies on:
3) chronic oral toxicity
4) reproduction toxicity including prenatal developmental toxicity
5) carcinogenicity
Further studies providing additional information necessary for the assessment of the safety of the
active substance and its residues should be conducted if there is any reason for concern. This could
include in vitro and in silico studies (e.g. read-across among substances with similar chemical
structures) to improve understanding of toxicity mechanisms and to compare the toxicity of parent
substance with its metabolites.
Toxicological studies on particular metabolites may be necessary if metabolic proximity cannot be
demonstrated between the target species and the laboratory test species. If toxicological data are
available from studies in humans, these should be taken into consideration.
2.2.1. Genotoxicity studies
To identify active substances and, if appropriate, their metabolites and degradation products with
mutagenic and genotoxic properties, a selected combination of different genotoxicity tests should be
carried out. The in vitro tests should be performed with and without mammalian metabolic activation
system, and the compatibility of the test material with the test system should be taken into account.
The following two in vitro tests are recommended as the ﬁrst step (EFSA Scientiﬁc Committee,
2011):
– a bacterial reverse mutation test (OECD guideline 471), and
– an in vitro mammalian cell micronucleus test (OECD guideline 487).
This combination of tests fulﬁls the basic requirements to cover the three genetic endpoints with
the minimum number of tests; the bacterial reverse mutation assay covers gene mutations and the
in vitro micronucleus test covers both structural and numerical chromosome aberrations.
Consideration should be given to whether speciﬁc features of the test substance might require
substitution or integration of one or more of the recommended in vitro tests with other in vitro or
in vivo tests in the basic battery. In the event of positive results from the in vitro battery, all the
available relevant data on the test substance should be reviewed, and where necessary, an appropriate
in vivo study (or studies) should be conducted to assess whether the genotoxic potential observed
in vitro is expressed in vivo.
The following in vivo tests are recommended as follow-up studies:
– a mammalian erythrocyte micronucleus test (OECD guideline 474),
– a transgenic rodent somatic and germ cell gene mutation assays (OECD guideline 488),
– an in vivo Comet assay (OECD guideline 489).
The in vivo micronucleus test covers the endpoints of structural and numerical chromosomal
aberrations and is an appropriate follow-up for in vitro clastogens and aneugens. There may be
circumstances in which an in vivo mammalian bone marrow chromosome aberration test (OECD
guideline 475) may be an alternative follow-up test.
In the in vivo genotoxicity studies, in case of negative results, it is important that evidence of target
cell exposure is obtained and it may be necessary to consider other relevant tissues (e.g. site of
contact tissues for highly reactive substances which are not systemically available).
Transgenic rodent assays can detect point mutations and small deletions and are without tissue
restrictions. The in vivo Comet assay is considered a useful indicator test in terms of its sensitivity to
substances which cause gene mutations and/or structural chromosomal aberrations and can be applied
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to many target tissues. In order to reduce the number of animals used, a single rodent study
combining the analysis of different endpoints (e.g. micronucleus and comet assay) may be considered.
In speciﬁc situations, the use of other studies (e.g. mechanistic studies) may be considered in order
to deﬁne the in vivo genotoxic potential of a substance.
2.2.2. Subchronic oral toxicity studies
To investigate the subchronic toxic potential of the active substance, at least one study on a rodent
species must be submitted with duration of at least 90 days. If the information from a rodent study is
not a suitable basis for consumer risk assessment, a further study in a non-rodent species may be
required. The test item must be administered orally (preferably incorporated into the diet) with at least
three levels in addition to a control group to obtain a dose response. The highest dose used should
normally be associated with evidence of adverse effects. The lowest dose level should not produce any
evidence of toxicity.
Protocols for these studies should comply with the OECD guidelines 408 (rodents) or 409 (non-rodents).
2.2.3. Chronic oral toxicity studies
Based on the results of the basic set of studies, there could be an indication to perform a chronic
oral study, which should be performed in at least one species and should be of at least 12 months’
duration. The species chosen should be the most appropriate on the basis of all available scientiﬁc
data, including the results of the 90-day studies. The default species is the rat. If a second study is
necessary, another rodent or a non-rodent mammalian species should be used. The test item must be
administered orally (preferably incorporated into the diet) with at least three dose levels in addition to
a control group to obtain a dose response.
Protocols for these studies should comply with the OECD guideline 452.
2.2.4. Carcinogenicity studies
If there are indications, from previous tests and/or read-across, of a potential tumorigenic effect of
the test substance, either from genotoxic or non-genotoxic mechanisms, a carcinogenicity study should
be performed in order to derive a relevant point of departure. Investigations can be made by a
combined chronic toxicity/carcinogenicity study according to OECD guideline 453 or by a
carcinogenicity study according to OECD guideline 451. Other methods could be used if validated.
2.2.5. Reproduction toxicity studies
If there are indications, from previous toxicity studies and/or read-across, of a potential effect of
the test substance on the reproductive system, studies of reproductive function must be carried out.
These studies comprise:
1) a reproductive toxicity study in one species; and
2) prenatal developmental toxicity studies in two species.
The test item must be administered orally (preferably incorporated into the diet) at least at three
levels in addition to a control group to obtain a dose response.
2.2.5.1. Reproduction toxicity study
Protocols for the reproduction toxicity studies should comply with OECD guideline 416 (two-genera
tion reproduction toxicity) or 443 (extended one-generation reproductive toxicity study).
2.2.5.2. Prenatal developmental toxicity studies
The objective is to detect any adverse effects on the pregnant female and the development of the
embryo and foetus as a result of exposure through the gestation period. The preferred species are rats
and rabbits. If a study on one of the species shows adverse effects on the progeny in the absence of
maternal toxicity, there is no requirement to perform a study in a second species.
Protocols should be in line with OECD guideline 414.
Guidance on the safety of feed additives for consumers
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2017;15(10):5022
2.2.6. Other studies
Further studies should be conducted if there are reasons for concern not covered by the studies
listed above (e.g. if the pharmacodynamic properties of the active substance are such that there is a
potential for effects on particular organs or functions of the organism). Such studies may include
examination of pharmacological effects, effects in juvenile (prepubertal) animals, immunotoxicity,
neurotoxicity (including developmental neurotoxicity) and/or endocrine-mediated effects.
3. Required studies for different additives
For some additives (Section 3.1), safety for the consumer can be presumed without the need for
speciﬁc information. For all other additives, the number and type of studies needed to establish the
safety of the additive for the consumer will depend on the nature and use of the additive.
3.1. Additives for which no safety studies are required
No studies concerning the safety of use of the additive for the consumers (ADME, residue and
toxicological studies) are required for:
• additives for which no exposure of the target animals to the active substance (or related
substances, including contaminants) will occur. Appropriate analytical data to determine that
the active substance (or related substances) is not detectable in feed at the time of feeding
should be provided;
• additives for which evidence exists that the substance (and potential metabolites/degradation
products) is not signiﬁcantly absorbed in the target animal except additives with a measurable
fraction of nanoparticles;
• microorganisms considered by EFSA to qualify for the qualiﬁed presumption of safety (QPS)
approach to safety assessment or when its biology is sufﬁciently well known to allow
pathogenic/toxigenic strains to be excluded by direct testing4;
• enzymes and amino acids produced by microorganisms considered by EFSA to qualify for the
QPS approach to safety assessment;
• enzymes and amino acids produced by genetically modiﬁed microorganisms for which the
recipient strain is considered by EFSA to qualify for the QPS approach to safety assessment
and for which the molecular characterisation of the event does not give rise to concern;
• enzymes, not excluded above, for which there is evidence that low molecular weight material
(below 10,000 Da) has been removed from the product;
• silage additives where it can be demonstrated that the active substance(s) and agent(s) occur
as normal constituents of silage and use of the additive does not substantially increase their
concentration compared to silage prepared without use of the additive (i.e. where there is no
substantial change in exposure);
• food additives for which an acceptable daily intake (ADI) is not speciﬁed or which are
authorised or approved as components of foodstuffs in the European Union (EU) without any
restriction provided that the use as feed additive would not lead to a pattern of metabolites
different from that of the species (laboratory animals, humans) used to assess the safety of
the additive in food.
3.2. Additives for which a restricted set of safety studies is required
3.2.1. ADME studies
No ADME studies are required:
• if the active component(s) of the additive consists only of microorganisms, enzymes; or
• if the active substance(s) is naturally present in signiﬁcant amounts in food or feedingstuffs or
the substance as absorbed is a normal constituent of body ﬂuids or tissues; or
• for nutritional additives; or
• in the species covered in column 2 of Table 1 when these data are available for the relevant
species in column 1; or
4 For substances for reduction of the contamination of feed with mycotoxins based on QPS microorganisms, the effects of the
metabolites/degradation products on consumer safety should be studied.
Guidance on the safety of feed additives for consumers
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2017;15(10):5022
• in minor terrestrial species if data are available from three major terrestrial species (cattle, pigs
and chickens).
ADME studies are required for all substances not exempted above.
3.2.2. Residue studies
No residue studies are required if:
• the active component(s) of the additive consists only of microorganisms, enzymes, amino
acids, ‘vitamins pro-vitamins and chemically well-deﬁned substances, having similar effect’
which do not accumulate in tissues/products or ‘compounds of trace elements’ already
authorised; or
• the additive is intended to be used in:
– the species covered in column 2 of Table 1 if metabolic similarity with the relevant species
in column 1 of Table 1 is given or demonstrated,
– horses, if the residue pattern and distribution in a major ruminant and pigs are similar,
– all other food-producing animals (including rabbits but excluding ﬁsh and bees) if the
residue patterns and distribution in cattle, pigs and chicken are similar,
Provided that the concentrations of the additive in feed among the species are similar.
For the following substances, the requirement for residue data is limited to marker residue
(Section 2.1.2.2) concentrations comparing the tissue/products levels in an untreated group and in the
group supplemented with the highest proposed concentration without a withdrawal time:
• substances which are a natural constituent of body ﬂuids or tissues or are naturally present in
food or feedingstuffs if the use of the additive substantially increases the intake or tissue
retention;
• for colourants which add colour to food of animal origin;
• ‘vitamins, pro-vitamins and chemically well-deﬁned substances, having similar effect’ that have
a potential for accumulation in the tissues/products which are not already authorised;
• ‘compounds of trace elements’ not already authorised;
• additives already authorised in food for which a health-based guidance value is established.
A complete set of residue studies are required for all substances not exempted above.
3.2.3. Toxicological studies
Toxicological studies are not required for:
• non-xenobiotic chemicals highly puriﬁed (as a guide < 1% of unidentiﬁed material on a dry
matter basis).
• nutritional additives already authorised.
Toxicological studies are required for all additives not exempted above.
• For microorganisms and fermentation products, a basic set of toxicity studies should be
provided consisting of genotoxicity/mutagenicity tests and a subchronic (90-day) oral toxicity
study.
• For xenobiotic substances (deﬁned as chemicals which are not a natural component of the
organism exposed to them), the basic set of toxicological studies augmented as appropriate by
other studies (see Section 2.2).
In addition to the above, for substances for reduction of the contamination of feed by mycotoxins
that modify the chemical structure of mycotoxins the following should be considered:
• The mycotoxin metabolites/degradation products derived from the mycotoxin should be
identiﬁed.
• Any major metabolite(s)/degradation products(s) of the mycotoxin should be examined for
genotoxicity and for toxicity after oral administration and then compared to that of the parent
mycotoxin. The endpoints selected should include mycotoxin-speciﬁc effects if appropriate.
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3.3. Additives for which a complete set of safety studies are required
For all additives not exempted above, a complete set of studies listed under Section 2 should be
provided.
For coccidiostats and histomonostats (and potentially other additives, see Section 5), the data set
submitted should contain the elements necessary for establishing risk management tools as MRLs and
withdrawal periods.
4. Assessment of consumer safety
4.1. Determination of a safe dose
The safe dose is derived from the dose response of toxicological or pharmacological effects and
usually expressed as a NOAEL5 as mg per kg body weight (bw) per day. Where only a lowest observed
adverse effect level (LOAEL) is available or the distance between the dose levels tested is large, a
benchmark dose (BMD) (e.g. BMDL5 for continuous data, BMDL10 for quantal data) should be
calculated instead.
In general, the BMD approach can be used to derive a value which can substitute for a NOAEL. It
makes extended use of dose–response data and provides a quantiﬁcation of the uncertainty and
variability in the dose–response data. For details on how to apply the BMD approach, see the EFSA
guidance on ‘Use of the benchmark dose approach in risk assessment’ (EFSA Scientiﬁc
Committee,2017).
The overall NOAEL used for the risk characterisation of the substance is selected from the results of
all the studies available. In principle, the lowest NOAEL should be taken. Any deviation from this
principle should be fully justiﬁed. All ﬁndings from previous sections together with all other relevant
published data (including any relevant information on the effects of the active substance on human)
and, where appropriate, information on chemicals having a closely related chemical structure should
be taken into consideration.
4.2. Highest safe intake
The highest safe intake is given by health-based guidance value (e.g. ADI, tolerable upper intake
level (UL)) based on the outcome of toxicological studies and applying an appropriate uncertainty
factor (UF). The health-based guidance value (mg of active substance per kg bw per day) is derived
by dividing the selected reference point (e.g. NOAEL, BMDL, LOAEL) by an appropriate UF.
The UF used to determine the ADI of an active substance should take into consideration the nature
of the biological effects and the quality of the data used to identify the NOAEL. The overall default UF
of 100 (10x10 for inter- and intraspecies extrapolation) is normally used in calculating the ADI from
laboratory animal data provided that the toxicological package consists at least of genotoxicity studies,
a chronic study and reproduction studies. If the NOAEL of a subchronic study has to be used in place
of that of a chronic study, an additional UF of 2 should be applied (EFSA Scientiﬁc Committee, 2012).
Higher factors might be applied in order to account for additional sources of uncertainty in the data or
when the NOAEL is set on the basis of a particularly critical endpoint, such as prenatal development
toxicity or endocrine disruption. When data on the active substance are available for humans a lower
UF (≤ 10) may be used.
The use of an ADI for assessing consumer safety of feed additives normally requires that the
consumer of food derived from treated animals is exposed to a pattern of residues comparable to that
formed in the laboratory animal used for deriving that ADI. If metabolic proximity between the
laboratory animal used for deriving the ADI and the target species cannot be demonstrated, additional
toxicological studies with the metabolites speciﬁc to the target species should be done.
For some additives (e.g. nutritional additives), it may be more appropriate to base the safety
assessment on the UL. This is deﬁned as the maximum level of total chronic daily intake of a nutrient
(from all sources) judged (by national or international scientiﬁc bodies) to be unlikely to pose a risk of
adverse health effects to consumers or speciﬁc groups of consumers.
In the case of an additive which is not genotoxic or genotoxic and carcinogenic and for which a
health-based guidance value cannot be established, the margin of safety (MOS) approach may be used
5 For the purpose of determining consumer safety, the NOAEL from toxicological studies and the no observed effect level (NOEL)
from pharmacological studies are used in an equivalent manner.
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to conclude whether or not there would be a risk at the proposed maximum use level (EFSA ANS
Panel, 2012). The MOS is calculated as the ratio between the lowest NOAEL usually from a 90-day
subchronic toxicity study and the dietary exposure of consumers to the toxicologically relevant residue.
4.3. Consumer exposure
4.3.1. Consumption data
Consumption of edible tissues and products as derived from the EFSA Comprehensive European
Food Consumption Database (Comprehensive Database) will be used to assess exposure to residues
from the use of feed additives in different EU countries, age classes and special population groups.
The Comprehensive Database provides a compilation of existing national information on food
consumption at individual level. Details on how the Comprehensive Database is used are published
in the Guidance of EFSA (EFSA, 2011). For each EU country and age class, only the latest survey
available in the Comprehensive Database will be used. Within the dietary studies, subjects are
classiﬁed in different age classes as follows:
• Infants: < 12 months old
• Toddlers: ≥ 12 months to < 36 months old
• Other children: ≥ 36 months to < 10 years old
• Adolescents: ≥ 10 years to < 18 years old
• Adults: ≥ 18 years to < 65 years old
• Elderly: ≥ 65 years to < 75 years old
• Very elderly: ≥ 75 years old
While the residue data reported for feed additives refer to the raw agricultural commodities (RAC),
the Comprehensive Database includes consumption data for foods as consumed, such as composite
foods (e.g. pizza) and other single foods or ingredients (e.g. cheese). In order to match those
consumption data with the available residue data for feed additives, the consumption data reported in
the Comprehensive Database have been converted into RAC equivalents. This involved identiﬁcation
and quantiﬁcation of the single ingredients present in each composite food, and a subsequent
conversion of these single ingredients into their RACs by means of conversion factors, where relevant.
For assessing the exposure to feed additives, the following list of commodities will be considered
relevant: meat, fat, liver, other offals (including kidney), milk, eggs, honey, ﬁsh and seafood.
Consumption data for meat, fat, liver and other offals will be considered for mammals and poultry
separately.
4.3.2. Occurrence and residue data
The dossier should contain all relevant occurrence/residue data which allow the assessor to
estimate the total relevant occurrence/residues in the food commodities listed above (i.e. the
arithmetic mean plus two standard deviations or the highest single value in case of less than six
animals) resulting from the use of the additive as described by the applicant.
When assessing additives intended for multispecies use, the value for the species with the highest
concentration of residues in a given tissue of poultry, mammals and ﬁsh will be taken as representative
for that speciﬁc food commodity in all poultry, mammals and ﬁsh, respectively.
The residue concentration in muscle and fat (skin + fat for poultry) will be applied to the intake of
meat according to the following proportions: mammals 80% muscle and 20% fat, poultry 90% muscle
and 10% fat (skin + fat).
The residue concentration in kidney will be applied to the intake of other offals, while in the case of
poultry, the concentration of skin fat will be applied to the fat intake.
4.3.3. Exposure methodology
Depending on the nature of the health-based guidance derived, either a chronic or acute exposure
assessment may be required.
For chronic exposure assessments, dietary surveys with only one reporting day per individual will
not be considered as they are not adequate to assess repeated exposure. For each individual, the total
relevant residues will be combined with the average daily consumptions of the corresponding food
commodities, and the resulting exposures per food will be summed in order to obtain total chronic
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exposure at individual level (standardised by using the individual body weight). The mean and the
higher percentile (usually the 95th percentile) of the individual exposures will be subsequently
calculated for each dietary survey and each age class separately.
As opposed to the chronic exposure assessments, acute exposure will be assessed for all dietary
surveys available and will be carried out for each RAC value separately. In this case, the total relevant
residue for the commodity under assessment will be combined with the total corresponding
consumption within each single day. The higher percentile (usually the 95th percentile) exposures
based on the consuming days only will be calculated for each food commodity, dietary survey and age
class separately. In case the exposure assessment reveals more than one food commodity approaching
the health-based guidance value alternative scenarios including addition of acute exposures within a
single day may additionally be envisaged.
A web-based tool will be made available by EFSA, supporting assessors in the calculation of chronic
and acute exposure estimates according to the above methodology.
4.3.4. Outcome of the assessment
If the highest proposed feed concentration of an additive would result in a consumer exposure
exceeding the highest safe level, measures to reduce consumer exposure should be taken. These
measures could consist of a reduction of the proposed feed concentration of the additive and/or the
introduction of a withdrawal period and maximum residue limits, if necessary.
5. MRLs and withdrawal period
Where the levels of residues of an additive in food from animals fed with that additive might have
an adverse effect on human health, setting of MRLs for the active substance or for its metabolites in
the relevant foodstuffs of animal origin and a withdrawal period may be needed. MRLs are generally
not considered necessary if a withdrawal time is not required.
Maximum residue limit means the maximum concentration of residue (expressed as lg marker
residue per kg of edible wet tissue or product) which may be accepted by the EU to be legally
permitted or recognised as acceptable in food. It is based on the type and amount of residue
considered to be without any toxicological risk for human health as expressed by a health-based
guidance value. In principle, the MRL cannot be set in the absence of such a value.
The validity of the MRLs with respect to the exposure of consumers to total residues will be
evaluated using the approach as described in Section 5.1 (Figure 1).
For certain additives, residues could arise below the MRL values in milk, eggs or meat which could
nonetheless interfere with food quality in particular food-processing procedures. For such additives, it
may be appropriate to consider a ‘maximum (food product) processing compatible residue’ (MPCR) in
addition to establishing MRL values.
The withdrawal time comprises the period after cessation of the administration of the additive
which is necessary to enable the residue levels to fall below the MRLs. An experimental withdrawal up
to 12 h is considered a practical zero-day withdrawal.
5.1. Calculation of MRLs
Individual MRLs will ideally be set for the different tissues or products of target animal species. The
individual MRLs in different tissues/products will reﬂect the depletion kinetics and variability of the
residue levels within those tissues/products in the animal species. Variability is normally reﬂected by
using the 95% conﬁdence limit of the mean. If the conﬁdence limit cannot be calculated due to low
number of samples, the highest individual value should be taken instead. The deﬁnitions used in
deriving an MRL are listed in Table 2.
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Deriving a MRL is an iterative process which is summarised in Figure 1.
The different steps are the following:
i) select the minimum withdrawal time for which the exposure (dietary intake of total residues
(DITR)) is below the health-based guidance value. If that value is exceeded at each withdrawal
time for which data are available, a new data set should be generated using a longer
withdrawal time or lower dietary concentrations of the additive.
ii) for all tissues/products, calculate the ratios marker vs. total toxicologically relevant metabolites
corresponding to the withdrawal selected in step (i). Ideally, the ratio values will be in the same
range (similar) for all withdrawal times. In cases where a full data set is not available because
values fall below the limit of detection an extrapolation of ratio marker to total residues (RMTR)
may be acceptable.
Table 2: Deﬁnitions used in deriving an MRL
i-j Individual tissues/products (liver, kidney, muscle, skin + fat, milk, eggs) at different times
MRLi-j Maximum residue limit in tissues/products (lg marker substance/kg)
TRCi-j Total residue concentration in individual tissues/products (lg/kg)
MRCi-j Marker residue concentration for individual tissues/products (lg/kg)
RMTRi-j Ratio MRCi-j to TRCi-j for individual tissues/products
DITR Dietary intake of total residues (lg/kg body weight per day)
Calculation follows Section 4.3 (consumer exposure) by the use of a web-based tool provided by
EFSA
DITRM Dietary intake of total residues (lg/kg body weight per day) calculated from MRLs of individual
tissues/products divided by RMTR
Calculation follows Section 4.3 (consumer exposure) by the use of a web-based tool provided by EFSA
Figure 1: Rationale for setting MRLs
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iii) where the marker residue represents a major fraction of total residues and as total residue
concentrations (TRCs) and MRCs are determined in separate experiments, TRCs may appear to
be lower than MRCs which leads to ratios > 1. In that case, MRCs will be considered as the
reference and TRCs back calculated using the RMTR from another experiment, in which TRCs
and MRCs have been measured.
iv) considering the MRCs measured in the different tissues/products (including two standard
deviations or the highest values where a reduced number of animals is available as a guide),
and taking into consideration the limit of quantiﬁcation of the analytical method of the marker
residue in the different tissues/products, select a ﬁrst set of MRL values.
v) check whether the DITR MRL (DITRM) obtained from the proposed MRLs is below the health-
based guidance value and close to the DITR. If the health-based guidance is exceeded, then a
set of lower MRLs should be selected and the comparison repeated.
In all cases, an analytical method of sufﬁcient sensitivity must be available before MRLs can be set.
The limit of quantiﬁcation of the method should be at least three times lower than the MRL.
5.2. Existing MRLs
Where MRLs for an active substance are in force within EU (e.g. Regulation (EC) No 37/2010)6, the
assessment of the safety of the additive for the consumer is based on:
• a veriﬁcation that the toxicological data set submitted or retrieved from the updated scientiﬁc
literature would not modify the health-based guidance value on which the MRL is based,
• a marker residue study performed with the additive at the highest proposed use level.
If the concentration of residues in tissues and products is above the existing MRLs, the conditions
of use of the additive (e.g. withdrawal time, use level) should be reconsidered.
5.3. Extrapolation of MRLs
Provided that the levels of the additive in the feed of the different species considered are
essentially similar, MRLs for the different edible tissues and products can be extrapolated:
• within physiologically similar species (see Table 1). This would not exclude the setting of lower
MRLs for these species based on the outcome of residue studies.
• to horses when MRLs for a major ruminant and pigs exist.
• to all other minor species of food-producing animals except ﬁsh if identical MRLs were derived
in tissues of cattle, pigs and chicken.
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Glossary
Active agent Any viable microorganism intended to be used as/in a feed additive and
that provides the intended effect.
Active substance Any substance or mixture of substances intended to be used as/in a feed
additive and that provides the intended effect.
Excretion Process(es) by which an administered substance and/or its metabolites are
removed from the body (OECD guideline 417 (2010)).
Feed additive Substances, microorganisms or preparations other than feed materials and
premixtures which are intentionally added to feed or water in order to
perform one or more functions mentioned in Article 5.3 of Regulation (EC)
No 1831/2003.
Marker residue The residue selected for assay whose concentration is in a known relationship
to total residues in tissues and products, ideally constant during depletion.
Target tissue(s) The edible tissue(s) selected to monitor for residues in the target animals,
including, where appropriate, milk or eggs.
Tolerable upper intake
level (UL)
Maximum level of total chronic daily intake of a nutrient (from all sources)
judged (by national or international scientiﬁc bodies) to be unlikely to pose a
risk of adverse health effects to consumers or speciﬁc groups of consumers
Withdrawal period The withdrawal time comprises the period after cessation of the
administration of the additive which is necessary to enable the residue
levels to fall below a level which does not pose a risk to consumers.
Xenobiotic Chemicals which are not a natural component of the organism exposed to
them. Physiological substances whose use results in much higher
concentrations than usual in the organism exposed to them may be treated
as xenobiotics.
Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
BMD benchmark dose
BMDL benchmark dose level
DITR dietary intake of total residues
DITRM dietary intake of total residues (calculated from proposed) MRLs
FEEDAP Panel EFSA Panel on Additives and Products or Substances used in Animal Feed
LOAEL lowest observed adverse effect level
MOS margin of safety
MPCR maximum (food product) processing compatible residue
MRC marker residue concentration
MRL maximum residue level
NOAEL no observed adverse effect level
NOEL no observed effect level
OECD Organisation for Economic Cooperation and Development
QPS qualiﬁed presumption of safety
RAC raw agricultural commodities
RMTR ratio marker to total residues
TRC total residue concentration
UF uncertainty factor
UL tolerable upper intake level
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